항암제동반진단사업단

INFORMATION & PAPER

정보광장

정보광장

INFORMATION & Paper

Home > 정보광장 > CDx

CDx

no.	Year	Title	Author	Journal
29	2010	Clinical development of biomarkers for personalized medicine]	M. Saito and T. Yoshino	Nihon Rinsho
28	2010	A growing family: adding mutated Erbb4 as a novel cancer target	U. Rudloff and Y. Samuels	Cell Cycle
27	2010	Biomarker-based prediction of response to therapy for colorectal cancer: current perspective	J. S. Ross, J. Torres-Mora, N. Wagle, T. A. Jennings and D. M. Jones	Am J Clin Pathol
26	2010	Biomarkers in lung oncology	R. Rosell, A. Vergnenegre, B. Liu, M. Cobo, B. Massuti, J. Wei, M. A. Molina, C. Costa, C. Queralt and M. Taron	Pulm Pharmacol Ther
25	2010	Combining targeted therapies: practical issues to consider at the bench and bedside	J. Rodon, J. Perez and R. Kurzrock	Oncologist
24	2010	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	P. J. Roberts, T. E. Stinchcombe, C. J. Der and M. A. Socinski	J Clin Oncol
23	2010	BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery	C. Printz	Cancer
22	2009	Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress	H. Wakelee, B. W. Loo, Jr., K. H. Kernstine, J. B. Putnam, Jr., M. J. Edelman, E. E. Vokes, J. H. Schiller, P. Baas, N. Saijo, A. Adjei, G. Goss, H. Choy and D. R. Gandara	Clin Lung Cancer
21	2009	Advances in personalized therapeutics in non-small cell lung cancer: 4q12 amplification, PDGFRA oncogene addiction and sunitinib sensitivity	C. Swanton and R. A. Burrell	Cancer Biol Ther
20	2009	UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?	C. Schulz, S. Boeck, V. Heinemann and H. J. Stemmler	Anticancer Drugs

First 41 42 43 44 45 46 47 48 49 50 Last

서울시 관악구 관악로1 서울대학교 생명공학공동연구원 81동 314호 | 대표번호 : 02-880-2850
COPYRIGHT ⓒ 항암제동반진단사업단. ALL RIGHTS RESERVED.